---
title: Patient eligibility for trials with imaging response assessment at the time
  of molecular tumor board presentation
date: '2024-06-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38849902/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240608181807&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Approximately one third of cancer patients with advanced
  solid malignancies are not eligible for treatment response assessment in trials
  with endpoints ORR or DOR at the time of MTB presentation. The rate of patients
  eligible for trials with imaging endpoints differs significantly based on the underlying
  malignancy and should be taken under consideration during the planning of new precision
  oncology ...'
disable_comments: true
---
CONCLUSION: Approximately one third of cancer patients with advanced solid malignancies are not eligible for treatment response assessment in trials with endpoints ORR or DOR at the time of MTB presentation. The rate of patients eligible for trials with imaging endpoints differs significantly based on the underlying malignancy and should be taken under consideration during the planning of new precision oncology ...